IL-6/STAT3/E-cadherin/EGFR信号通路在分割照射下鼻咽癌获得性放疗抵抗中的作用研究

基本信息
批准号:81272491
项目类别:面上项目
资助金额:65.00
负责人:胡国清
学科分类:
依托单位:华中科技大学
批准年份:2012
结题年份:2016
起止时间:2013-01-01 - 2016-12-31
项目状态: 已结题
项目参与者:庄亮,龙国贤,刘东伯,王峻峰,梅齐,彭慧,蒋继宗,李文雯,孙伟
关键词:
STAT3鼻咽癌放疗抵抗EcadherinEGFR
结项摘要

Local recurrence is the main reason for the failure of radiotherapy in nasopharyngeal carcinoma (NPC). Studies have shown that fractionated irradiation could induce radiation resistance in cancer cells,however, the molecular mechanism is unclear at present. Our previous studies have indicated that radiation therapy induced IL-6/STAT3 signal pathway activation in NPC cells, promoted pSTAT3 expression, downregulated the downstream gene E-cadherin expression and increased EGFR expression.On this basis, we propose hypotheses:fractionated irradiation induce IL-6/STAT3 pathway activation in NPC, downregulate its downstream gene E-cadherin expression, then transcriptionally upregulate EGFR expression which finally induces radiation resistance. A panel of nasopharyngeal carcinoma cell lines treated with different doses of radiation、local recurrent tissue and nude mouse xenograft model were experiment objects in this project. Immunohistochemistry, Confocal immunofluorescence,RT-PCR,RNA interference,Western,CHIP and EMSA techniques will be used to verify the hypotheses at cellular、tissue and in vivo level that IL-6/STAT3/E-cadherin/EGFR signaling pathway is the major molecular mechanism for radiation resistant induced by fractionated radiation in nasopharyngeal carcinoma cells, and explore the possible molecular mechanism of IL-6/STAT3/E-cadherin signaling pathway in transcriptional regulation of EGFR expression.

局部复发是鼻咽癌放疗失败的主要原因。研究表明肿瘤细胞在分次照射后会诱发放疗抵抗,而目前分子机制尚不明确。我们的前期研究显示放疗可以激活鼻咽癌IL-6/STAT3通路,促使pSTAT3表达增加,E-cadherin表达下降,EGFR表达增加。在此基础上,我们提出假设:分次照射后诱导鼻咽癌IL-6/STAT3通路激活,下调E-cadherin表达,继而转录调控EGFR的表达增加,从而诱发放疗抵抗。本项目拟利用接受不同照射剂量的鼻咽癌细胞株、放疗后局部复发组织以及裸鼠移植瘤模型作为研究对象,用免疫组化、免疫荧光共聚焦、RT-PCR、RNA干扰、Western、CHIP以及EMSA等技术,分别从细胞、组织、体内水平验证IL-6/STAT3/E-cadherin/EGFR信号通路是诱导鼻咽癌细胞分次照射后放疗抵抗的主要分子机制之一的理论假设,并探索E-cadherin调控EGFR表达的可能分子机制。

项目摘要

局部复发是鼻咽癌放疗失败的主要原因。研究表明肿瘤细胞在分次照射后会诱发放疗抵抗,而目前分子机制尚不明确。我们的前期研究显示放疗可以激活鼻咽癌IL-6/STAT3通路,促使pSTAT3表达增加,E-cadherin表达下降,EGFR表达增加。在此基础上,我们提出假设:分次照射后诱导鼻咽癌IL-6/STAT3通路激活,下调E-cadherin表达,继而转录调控EGFR的表达增加,从而诱发放疗抵抗。本次实验我们发现放疗可以诱导鼻咽癌细胞出现EMT表型改变,同时可以促使鼻咽癌细胞IL-6分泌水平增高。给予外源性的IL-6可以增强鼻咽癌的侵袭转移能力,同时外源性的IL-6可以诱导鼻咽癌发生EMT.我们过表达下游转录因子twist1, 发现上调twist1 可能通过激活IL-6/STAT3/E-cadherin/EGFR信号通路参与调节放疗后的损伤修复进而诱导放疗抵抗。研究表明IL-6/STAT3/E-cadherin/EGFR信号通路是诱导鼻咽癌细胞分次照射后放疗抵抗的主要分子机制之一,twist1通过激活IL-6/STAT3/E-cadherin/EGFR信号通路诱导鼻咽癌放疗抵抗,为鼻咽癌放疗抵抗的研究提供新方向。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function

An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function

DOI:10.1080/15476286.2017.1377868.
发表时间:2017
2

In situ construction of hybrid Co(OH)2 nanowires for promoting long-term water splitting

In situ construction of hybrid Co(OH)2 nanowires for promoting long-term water splitting

DOI:10.1016/j.apcatb.2021.120063
发表时间:2021
3

基于TGF-β1信号通路研究小檗碱联合芒柄花黄素抑制鼻咽癌细胞迁移的作用机制

基于TGF-β1信号通路研究小檗碱联合芒柄花黄素抑制鼻咽癌细胞迁移的作用机制

DOI:10.7501/j.issn.0253-2670.2022.10.015
发表时间:2022
4

Critical role of VGLL4 in the regulation of chronic normobaric hypoxia-induced pulmonary hypertension in mice

Critical role of VGLL4 in the regulation of chronic normobaric hypoxia-induced pulmonary hypertension in mice

DOI:10.1096/fj.202002650RR
发表时间:2021
5

Arsenic species in electronic cigarettes: Determination and potential health risk

Arsenic species in electronic cigarettes: Determination and potential health risk

DOI:10.1016/j.jes.2020.01.023
发表时间:2020

相似国自然基金

1

分割放射下,谷氨酸/EGLN1/SNAIL信号通路参与鼻咽癌放疗抵抗的作用机制研究

批准号:81773231
批准年份:2017
负责人:胡国清
学科分类:H1821
资助金额:55.00
项目类别:面上项目
2

分割照射下,Snail介导上皮间质转化与肿瘤细胞“干性”调控鼻咽癌放疗抵抗的作用机制研究

批准号:81572960
批准年份:2015
负责人:胡国清
学科分类:H1821
资助金额:52.00
项目类别:面上项目
3

Metformin抑制IL-6/STAT3信号途径克服肺癌EGFR-TKI获得性耐药的作用和机制

批准号:81172113
批准年份:2011
负责人:何勇
学科分类:H1821
资助金额:60.00
项目类别:面上项目
4

Twist/EGFR/DNA-PK,分割照射下宫颈癌获得性放射拮抗的新机制?

批准号:81101691
批准年份:2011
负责人:熊慧华
学科分类:H1816
资助金额:22.00
项目类别:青年科学基金项目